Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma

Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels

(2013) Ahmedin Jemal et al.   JNCI-Journal of the National Cancer Institute

A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence

(2013) Joanna Kaplon et al.   NATURE

Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

(2013) E. J. Morris et al.   Cancer Discovery

Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines

(2012) Ji Eun Kim et al.   BMC CANCER

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis

(2012) L. C. W. Vredeveld et al.   GENES & DEVELOPMENT

An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice

(2012) Kathryn M. Kinross et al.   JOURNAL OF CLINICAL INVESTIGATION

Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

(2012) S. M. Brachmann et al.   MOLECULAR CANCER THERAPEUTICS

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas

(2011) William E. Damsky et al.   CANCER CELL

Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult Mouse

(2011) R.-P. Charles et al.   CANCER RESEARCH

Nuclear PTEN Regulates the APC-CDH1 Tumor-Suppressive Complex in a Phosphatase-Independent Manner

(2011) Min Sup Song et al.   CELL

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

(2011) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Interferon-γ links ultraviolet radiation to melanomagenesis in mice

(2011) M. Raza Zaidi et al.   NATURE

BRAF targeted therapy changes the treatment paradigm in melanoma

(2011) Antoni Ribas et al.   Nature Reviews Clinical Oncology

Oncogene-induced senescence and melanoma: where do we stand?

(2011) Daniel S. Peeper   Pigment Cell & Melanoma Research

Meeting report from the 2011 international melanoma congress, Tampa, Florida

(2011) Keiran S. M. Smalley et al.   Pigment Cell & Melanoma Research

The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin

(2011) David C. Whiteman et al.   Pigment Cell & Melanoma Research

Characterization of Melanoma Cells Capable of Propagating Tumors from a Single Cell

(2010) M. A. Held et al.   CANCER RESEARCH

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis

(2010) C Nogueira et al.   ONCOGENE

Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice

(2009) Nathalie Dhomen et al.   CANCER CELL

AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer

(2009) Krishna M. Vasudevan et al.   CANCER CELL

BrafV600E cooperates with Pten loss to induce metastatic melanoma

(2009) David Dankort et al.   NATURE GENETICS

Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice

(2009) V K Goel et al.   ONCOGENE

PTEN downregulates p75NTR expression by decreasing DNA-binding activity of Sp1

(2008) Sherri L. Rankin et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

(2008) N. Rhodes et al.   CANCER RESEARCH

The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel

(2008) N. K. Haass et al.   CLINICAL CANCER RESEARCH

Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase

(2008) Dirk A. Heerding et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†

(2008) Adrian J. Folkes et al.   JOURNAL OF MEDICINAL CHEMISTRY

Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival

(2008) Robert A. Cartlidge et al.   Pigment Cell & Melanoma Research